作者
Chris Parker,Sten Nilsson,Daniel Heinrich,Svein Inge Helle,Joe M. O’Sullivan,Sophie D. Fosså,Aleš Chodacki,Paweł Wiechno,John Logue,M. Seke,Anders Widmark,Dag Clement Johannessen,Peter Hoskin,David Bottomley,Nicholas D. James,A. Solberg,Isabel Syndikus,J. Kliment,Saskia Wedel,S. Boehmer,Marcos F. Dall’Oglio,Lars Franzén,Robert E. Coleman,Nicholas J. Vogelzang,C. Gillies O'Bryan-Tear,K. Staudacher,J. Garcia‐Vargas,Minghua Shan,Øyvind S. Bruland,Oliver Sartor
摘要
Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with alpha particles. We assessed the efficacy and safety of radium-223 as compared with placebo, in addition to the best standard of care, in men with castration-resistant prostate cancer and bone metastases.
爱静静
科研小民工
请叫我风吹麦浪
VDC
故意的傲玉
Jenny
杳鸢
iNk
petrichor
Loooong
迟大猫
sutharsons
HEIKU
坚强亦丝
习习
Agernon
小林太郎
buno
pcr163
YifanWang
皖公网安备34019202002308
